SCHEMBL9396355

SCHEMBL9396355

O=c1c(CCl)cc2ccccc2n1Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.51
HPGD P15428 2/20 0.51
LMNA P02545 1/20 0.51
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 2/20 0.49
GAA P10253 1/20 0.49
HTT P42858 1/20 0.49
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
CFTR P13569 2/20 0.48
P2RX4 Q99571 1/20 0.46
SRC P12931 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
ESR1 P03372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13531041 0.88 CCR2 (0.55) CCR2SMN1; SMN2HPGDLMNAKDM4E
SCHEMBL9754467 0.84 CYP19A1 (0.50) CCR2SMN1; SMN2HPGDLMNAKDM4E
SCHEMBL29200758 0.81 HPGD (0.60) CCR2SMN1; SMN2HPGDLMNAKDM4E
SCHEMBL30783420 0.81 HPGD (0.60) CCR2SMN1; SMN2HPGDLMNAKDM4E
SCHEMBL9423360 0.77 CYP19A1 (0.55) CCR2SMN1; SMN2HPGDLMNAKDM4E
SCHEMBL11536101 0.77 CCR2 (0.66) CCR2SMN1; SMN2HPGDLMNAKDM4E
SCHEMBL30884510 0.77 CCR2 (0.66) CCR2SMN1; SMN2HPGDLMNAKDM4E
SCHEMBL9423391 0.76 ALDH1A1 (0.49) HPGDKDM4EALDH1A1GAAMEN1
SCHEMBL9356192 0.76 CNR1 (0.53) CCR2SMN1; SMN2HPGDLMNAKDM4E
SCHEMBL30162776 0.76 DAO (0.57) SMN1; SMN2HPGDLMNAKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5318971-A Also antihyperproliferative skin disease agents, e.g. psoriaisis; side effect reduction SCHERING CORPORATION (US) 1994-06-07 US disclosed
EP-0593461-A1 3-SUBSTITUTED-1-(ARYL OR ARYLALKYL)-2(1H)-QUINOLINONES SCHERING CORPORATION (US) 1994-04-27 EP disclosed
US-5064837-A Antiallergens SCHERING CORPORATION (US) 1991-11-12 US disclosed
WO-1991007401-A1 3-SUBSTITUTED-1-(ARYL OR ARYLALKYL)-2(1H)-QUINOLINONES SCHERING CORPORATION (US) 1991-05-30 WO disclosed